Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone
Bypasses Union Objections To Downsizing
Executive Summary
Hudson finds solution for legacy sites which have dogged predecessors.
You may also be interested in...
Sanofi API Unit Expects $1bn Sales By 2022
Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.
Sanofi Highlights MS Asset After Solid Q4
The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis.
Vertex’s $5bn Alpine Buyout Builds Autoimmune Disease Presence
The company hopes for a “Humira-like” blockbuster with povetacicept, the object of the sector’s biggest M&A deal so far this year.